. home.aspx



PureTech’s Vedanta raises $27m for microbiome research

December 24, 2018 / pharma phorum

US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and food allergy. Investors include the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health. Proceeds from the financing will be used to advance the company’s pipeline, including a phase 1b/2 study of VE800 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) in advanced or metastatic cancers, a phase 2 study of VE303 in recurrent Clostridium difficile infection (rCDI), and a phase 1/2 study of VE416 in food allergy. The connection between the microbiome and the immune system has been an area of increasing interest for pharma over the last few years, and studies suggest that checkpoint inhibitor drugs like Opdivo are significantly amplified when combined with beneficial bacterial. Vedanta was founded by PureTech ...